This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Genelux Corporation
Information provided by (Responsible Party):
Kaitlyn Kelly, MD, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT02714374
First received: March 2, 2016
Last updated: June 26, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells. Vaccinia virus has been used successfully in the past as smallpox vaccine in millions of people worldwide.

Condition Intervention Phase
Solid Organ Cancers Biological: GL-ONC1 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Non-randomized Phase 1b Study to Investigate the Safety and Effect of the Oncolytic Virus GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery for Curative-Intent or Palliative Resection

Resource links provided by NLM:


Further study details as provided by Kaitlyn Kelly, MD, University of California, San Diego:

Primary Outcome Measures:
  • Number of participants with treatment-related adverse events as defined by CTCAE v4.03. [ Time Frame: 2.5 years ]

Secondary Outcome Measures:
  • The presence of GL-ONC1 within malignant tumors by examination of the resected surgical specimen. [ Time Frame: 2.5 years ]
  • The maximum concentration (Cmax) of GL-ONC1 in blood after administration [ Time Frame: 2.5 years ]
  • Level of anti-vaccinia neutralizing antibodies in serum [ Time Frame: 2.5 years ]
  • Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue [ Time Frame: 2.5 years ]

Estimated Enrollment: 36
Study Start Date: March 2016
Estimated Study Completion Date: March 2021
Estimated Primary Completion Date: March 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GL-ONC1
Cohort 3, 5, 7, 8, 9
Biological: GL-ONC1

Dose and Regimen:

  1. Single dose group: Cohort 1 dose is 1 × 109 pfu
  2. Multiple dose groups:

    • Cohort 2 dose is 1 × 109 pfu × 5 consecutive days
    • Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days
    • Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.

Route: GL-ONC1 is delivered as a bolus IV injection.


Detailed Description:

This is an open-label, non-randomized Phase 1b dose escalation study evaluating the safety and effect of the oncolytic virus GL-ONC1 administered intravenously, with or without eculizumab, prior to surgery in patients with advanced solid organ tumors.

GL-ONC1 is a genetically engineered oncolytic vaccinia virus, which disrupts nonessential genes and expression of the foreign gene expression. Evidence suggest that GL-ONC1 is able to infect tumor tissue and kill tumor cells.

The goals of this study are to evaluate the safety of GL-ONC1 and to assess the pharmacokinetics and pharmacodynamics profile of GL-ONC1 in vivo.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically-proven diagnosis of advanced (AJCC, 7th Edition: stage III or IV) or aggressive solid organ cancer.
  • Patients must provide written consent for a core needle biopsy sample of tumor tissue (primary or metastatic).
  • Have evidence of measurable disease (according to RECIST Version 1.1: http:// www.recist.com).
  • Have an ECOG Performance Score of 0 to 2.
  • Have a life expectancy of at least 3 months.
  • Have adequate organ and marrow function
  • Negative serum pregnancy test for females of childbearing potential.
  • Have negative test result for HIV and Hepatitis B or C testing.
  • Have baseline anti-vaccinia antibody titer < 10.

Exclusion Criteria:

  • Current or anticipated use of other investigational agents or marketed anticancer agent while on study (from the time of enrollment through the time of surgery).
  • Patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study.
  • Small pox vaccination for 4 weeks before study therapy and during study treatment.
  • Have received prior gene therapy or therapy with cytolytic virus of any type.
  • Have clinically significant cardiac disease
  • Oxygen saturation <90% measured by pulse oximetry at rest.
  • Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246) during the course of study.
  • Have known allergy to ovalbumin or other egg products.
  • Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers)
  • Have a history of allergy to iodinated contrast media.
  • Patients with known brain metastases
  • Pregnant or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02714374

Locations
United States, California
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
Kaitlyn Kelly, MD
Genelux Corporation
Investigators
Principal Investigator: Kaitlyn Kelly, MD University of California, San Diego
  More Information

Responsible Party: Kaitlyn Kelly, MD, Assistant Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02714374     History of Changes
Other Study ID Numbers: 151060
Study First Received: March 2, 2016
Last Updated: June 26, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Kaitlyn Kelly, MD, University of California, San Diego:
GL-ONC1
Solid Organ Cancer
Cancer
Surgery
Oncolytic Virus
Soliris
Metastatic melanoma
Esophageal and gastric adenocarcinoma (Stage III/IV)
Cholangiocarcinoma
Pancreatic adenocarcinoma
Gallbladder cancer
Colorectal cancer (Stage IV)
High-grade mucinous appendix cancer
High-grade gastrointestinal neuroendocrine cancer
Mesothelioma
High-grade soft tissue sarcoma
Stage III or IV

ClinicalTrials.gov processed this record on August 18, 2017